Background: The importance of passive immunotherapy in the battle against SARS-CoV-2 has been practically evidenced in China, the epicenter of COVID-19. In this perspective, I aimed to summarize recent updates regarding the use of convalescent plasma to contain COVID-19, and to make passive immunotherapy readily accessible as a preventive and treatment option in resource limited countries like Ethiopia.

Methods: An inclusive literature search was made using PubMed and Google scholar databases to recover published studies about convalescent plasma therapy for COVID-19 until June 2, 2020. Original studies that reported SARS-CoV-2 RNA level, clinical symptoms and/or mortality rates of COVID-19 patients after convalescent plasma treatment were considered in this study.

Results: Although no serious research has been done to address the effect of passive immunotherapy on COVID-19 at the time of writing this article, evidence from pilot studies indicated notable results of passive immunotherapy against COVID-19. Moreover, the included piolet studies indicated that convalescent plasma has to be prepared from locally recovered COVID-19 patients and readily available as a preventive and treatment option on the pipeline.

Conclusion: Although a large scale randomized clinical trials are warranted, convalescent plasma therapy has showed better treatment options, and has to be used in combination with standard supportive care until a specific drug of interest against COVID-19 is discovered.

Keywords: Passive immunotherapy, Convalescent plasma therapy, SARS-CoV-2, COVID-19, Ethiopia